<DOC>
	<DOCNO>NCT02259868</DOCNO>
	<brief_summary>1 . To investigate relative bioavailability ( BA ) improve tablet formulation candidate determine formulation develop use late Phase II Phase III clinical trial 2 . To investigate relative BA pediatric suspension , compare current 1B formulation 3 . To investigate bioequivalence ( BE ) BILR 355 BS two tablet strength ; three 25mg tablet vs. one 75 mg tablet , current 1B formulation</brief_summary>
	<brief_title>Study New Tablet Formulations Suspension Formulation Compared Current ( 1B ) Formulation BILR 355 BS Healthy Male Volunteer Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Healthy HIV negative adult male volunteer 2 . Age ≥18 ≤ 60 year 3 . BMI ≥18.5 BMI ≤29.9 kg/m2 4 . Ability give sign dated write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local regulation 1 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 2 . Surgery gastrointestinal tract ( except appendectomy ) 3 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 4 . History relevant orthostatic hypotension , faint spell blackouts 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator 7 . Intake drug long halflife ( &gt; 24 hour ) within least one month prior study drug administration trial 8 . Use drug within 10 day prior administration trial might reasonably influence result trial 9 . Participation another trial investigational drug within two month prior administration trial 10 . Current smoker 11 . Alcohol abuse ( 60 g/day ) 12 . Drug abuse ( positive urine test illicit prescription nonprescription drug drug abuse ) . 13 . Blood donation ( 100 mL within four week prior study drug administration trial ) 14 . Excessive physical activity ( within one week prior study drug administration trial ) 15 . Any laboratory value outside reference range clinical relevance screening , accord judgment investigator 16 . Inability comply dietary regimen require protocol 17 . Infected hepatitis B hepatitis C virus ( define either hepatitis B surface antigen , hepatitis C antibody positive</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>